Circadian Technologies Limited  

(Public, ASX:CIR)   Watch this stock  
Find more results for Mike Fisher´┐Ż
0.000 (0.00%)
Oct 1 - Close
ASX data delayed by 20 mins - Disclaimer
Currency in AUD
Range     -
52 week 0.14 - 0.25
Open     -
Vol / Avg. 0.00/52,257.00
Mkt cap 29.29M
P/E     -
Div/yield     -
EPS -0.06
Shares 148.09M
Beta     -
Inst. own     -
Nov 18, 2015
Circadian Technologies Ltd Annual Shareholders Meeting (Estimated) - 11:00AM GMT+11 - Add to calendar

Key stats and ratios

Q2 (Jun '15) 2015
Net profit margin -415.91% -575.18%
Operating margin -695.68% -899.40%
EBITD margin - -895.30%
Return on average assets -19.08% -29.61%
Return on average equity -21.66% -34.90%
Employees 5 -
CDP Score - -


Suite 0403 Level 4, 650 Chapel Street, South Yarra
+61-3-98260399 (Phone)
+61-3-98240083 (Fax)

Website links


Circadian Technologies Limited is an Australian-based company engaged in angiogenesis-based treatments for cancer. The Company is focused on a class of drug targets called Vascular Endothelial Growth Factors (VEGFs), develops therapies to extend and improve the lives of cancer sufferers. It has commercial partnerships with other biotechnology companies for the development of products based on its technology. The Company is into developing a variety of drugs to block the interaction between VEGF Receptor-3 (VEGFR-3) and its ligands VEGF-C and VEGF-D. Circadian Technologies Limited’s subsidiaries are Ceres Oncology Pty Ltd, 100% subsidiary granted exclusive rights to develop VGX-100 for oncology therapeutic applications; Opthea Pty Ltd, 100% subsidiary granted exclusive rights to develop VGX-100 and VGX-300 in the field of eye disease therapy; and Precision Diagnostics Pty Ltd, granted an exclusive license to Vegenics IP in the field of research reagents and clinical diagnostics.

Officers and directors

Megan Baldwin Ph.D. Chief Executive Officer, Managing Director, Director
Michael Tonroe Chief Financial Officer, Company Secretary
Richard Chadwick Ph.D. Head - Intellectual Property
Mike Gerometta Head of CMC Development
Ian Leitch Director - Clinical Research
Dominique Gayle Fisher Non-Executive Chairman of the Board
Russell John Howard Ph.D. Non-Executive Director
Tina Renna McMeckan Non-Executive Director